Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent's CAR-T Therapy Awarded Breakthrough Status in China

publication date: Feb 25, 2021

Innovent Biologics of Suzhou and IASO, a Bay Area-Nanjing biopharma, announced their partnered CAR-T candidate was granted Breakthrough Therapy status in China. The BTD designation for CT103A is based on results from an ongoing China Phase I/II trial in patients with relapsed or refractory multiple myeloma. CT103A is a fully-human anti-B-cell maturation antigen targeted CAR-T cell therapy that uses a lentivirus as a gene vector to transfect autologous T cells. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021